Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac COVID-19 Jab's Low Efficacy Said To Be Caused By Vaccine's Low Dosage

06/18/2021 | 02:43am EDT


ę MT Newswires 2021
All news about CUREVAC N.V.
07/20EU begins real-time review of Sanofi-GSK COVID-19 vaccine
RE
07/05S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses -govt off..
RE
07/04S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses -govt off..
RE
07/01AFTER HOURS WATCH LIST SCORECARD : Usws, cvac
MT
07/01SECTOR UPDATE : Health Care Stocks Post Solid Gains Thursday
MT
07/01SECTOR UPDATE : Health Care Stocks Outpacing Most Other Sectors This Afternoon
MT
07/01GLOBAL MARKETS LIVE : Amazon, The Gap, Fod, Lockheed Martin, CureVac...
07/01SECTOR UPDATE : Health Care Stocks Steady Premarket Thursday
MT
07/01Wall Street Sees Narrowly Mixed Open; Weekly Jobless Claims Fall
MT
07/01EUROPEAN MIDDAY BRIEFING : Stocks Jump to Open -2-
DJ
More news
Financials
Sales 2021 486 M 572 M 572 M
Net income 2021 341 M 401 M 401 M
Net cash 2021 2 745 M 3 234 M 3 234 M
P/E ratio 2021 16,4x
Yield 2021 -
Capitalization 18 210 M 21 497 M 21 455 M
EV / Sales 2021 31,8x
EV / Sales 2022 3,07x
Nbr of Employees 505
Free-Float 44,1%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 45,91 €
Average target price 63,03 €
Spread / Average Target 37,3%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean StÚphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-33.14%21 497
MODERNA, INC.221.50%140 065
LONZA GROUP AG20.60%55 634
IQVIA HOLDINGS INC.38.02%47 396
CELLTRION, INC.-26.46%31 265
SEAGEN INC.-18.34%25 955